Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Utah Medical ProductsUTMD +0.41%73 Debt-to-EBITDA is 0.02 as of Jun. 2026, which is at its 10-year median of 0.02. GuruFocus rates UTMD with a GF Score™ of 73/100 and a GF Value™ of $57.89 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 475 Medical Devices & Instruments companies, Utah Medical Products ranks better than 97.89% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Utah Medical Products's Debt-to-EBITDA or its related term are showing as below:
UTMD'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.02
Current: 0.02
During the past 13 years, the highest Debt-to-EBITDA Ratio of Utah Medical Products was 0.02. The lowest was 0.01. And the median was 0.02.
UTMD's Debt-to-EBITDA is ranked better than 97.89% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 1.61
vs UTMD: 0.02
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Utah Medical Products Debt-to-EBITDA Related Terms
Utah Medical Products Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Utah Medical Products's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UTMD vs EMBC, SMTI, PDEX: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Utah Medical Products's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Utah Medical Products Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Utah Medical Products's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Utah Medical Products's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Utah Medical Products (UTMD) has a Debt-to-EBITDA of 0.02 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Utah Medical Products. This is near median its historical median of 0.02. Over the past decade, Utah Medical Products' Debt-to-EBITDA has ranged from 0.01 to 0.02. According to the industry distribution chart, Utah Medical Products ranks #10 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 2.1%.
Is Utah Medical Products' Debt-to-EBITDA too high?
Utah Medical Products' current Debt-to-EBITDA of 0.02 is near median its 10-year median of 0.02. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.02. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.61. Utah Medical Products' value of 0.02 is 98.8% below this industry median. Based on the distribution chart, Utah Medical Products ranks #10 out of 475 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Utah Medical Products has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Utah Medical Products' Debt-to-EBITDA compare to EMBC and SMTI?
According to the Medical Devices & Instruments industry distribution chart, Utah Medical Products ranks #10 out of 475 companies for Debt-to-EBITDA. This places Utah Medical Products in the top 2% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.61. Utah Medical Products' value of 0.02 is 98.8% below this benchmark. Historically, Utah Medical Products' own Debt-to-EBITDA has ranged from 0.01 to 0.02 over the past decade. While the company's 10-year median is 0.02 vs. the industry median of 1.61, Utah Medical Products has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.61, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Utah Medical Products's current Debt-to-EBITDA of 0.02 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Utah Medical Products. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Utah Medical Products's current Debt-to-EBITDA is 0.02, which is near median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Utah Medical Products stock overvalued right now?
Based on GuruFocus' analysis, Utah Medical Products (UTMD) is currently considered Modestly Overvalued. The stock's GF Value™ is $57.89, compared to a current price of $70.84 — trading 22.4% above its estimated fair value. The current Debt-to-EBITDA is 0.02, which is near median its 10-year median of 0.02 and 98.8% below the Medical Devices & Instruments industry median of 1.61. Utah Medical Products' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Utah Medical Products (UTMD), the current Debt-to-EBITDA is 0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Utah Medical Products (UTMD) Overvalued in 2026?
Based on GuruFocus' analysis, Utah Medical Products stock appears to be overvalued.
The current stock price of $70.84 is trading 22.4% above its estimated GF Value™ of $57.89.
GuruFocus considers Utah Medical Products to be Modestly Overvalued.
Key valuation signals for UTMD:
Debt-to-EBITDA: 0.02 (near median its 10-year median of 0.02)
GF Value™: $57.89 vs. price of $70.84 (22.4% above fair value)
Industry Position: 98.8% below the Medical Devices & Instruments median (#10 of 475)
No single metric tells the full story. See the UTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
73GF Score
Get the complete analysis for UTMD
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTMD has been successfully added to your 
